<p><em>协议扩大了 Cardio Diagnostics 在全球的影响力，并支持在印度改善冠心病的检测和管理。</em></p>
<p>芝加哥 --（商业资讯）--Cardio Diagnostics Holdings, Inc.（纳斯达克：CDIO），一家在表观遗传学和人工智能驱动的精准心血管医学领域的领导者，Aimil Ltd.，自 1932 年以来在印度仪器行业处于前沿，向其广泛的医疗网络引入来自全球的创新一流技术，以及 Dr. Lal PathLabs，印度最受信赖的诊断及相关医疗测试服务提供商之一，拥有 290 多个临床实验室和 300 多名内部网络的医学博士，今天宣布达成战略协议，在印度推出 Cardio Diagnostics 的 PrecisionCHD™测试，以检测和管理冠心病（CHD）。</p>
<p>此次合作标志着 Cardio Diagnostics 首次在美国以外扩展，并正式进入印度市场。这也是朝着使 Cardio Diagnostics 的先进技术在印度可及迈出的重要一步，在印度，心血管疾病仍然是一个主要且日益严重的健康问题。冠心病在印度的流行率因人群设置而异，农村和城市地区的流行率分别高达 7.4% 和 13%。</p>
<p>PrecisionCHD 是一种临床血液检测，可以通过结合表观遗传学和遗传学的科学与人工智能技术，在分子水平上检测冠心病。这种经过临床验证的测试提供可操作的见解，帮助医生理解疾病的关键分子驱动因素，这对个性化治疗和持续管理至关重要。除了检测阻塞性冠心病（也可以通过血管造影检测到），PrecisionCHD 测试还可以检测非阻塞性冠心病，而血管造影通常无法检测到。支持 PrecisionCHD 检测无阻塞冠状动脉缺血（INOCA）和无阻塞冠状动脉心肌梗死（MINOCA）的数据，最近在美国心脏协会在路易斯安那州新奥尔良举行的科学会议上进行了展示。</p>
<p>此次合作的初始阶段已经开始，重点是将测试整合并推广到 Dr. Lal PathLabs 广泛的实验室和临床网络中，确保与印度的临床和监管协议保持一致。一旦建立，将重点放在加速商业推广上，预计将在 2026 年进行。</p>
<p>“我们很高兴与 Aimil 和 Dr. Lal PathLabs 合作，将 PrecisionCHD 引入印度，” Cardio Diagnostics 的首席执行官兼联合创始人 Dr. Meesha Dogan 表示。“这次合作是使先进心血管诊断普及的重要一步，也是我们不断努力将技术推广到美国市场以外的结果。”</p>
<p>“与 Cardio Diagnostics 和 Dr. Lal PathLabs 的合作使我们能够提供尖端的心血管诊断，改变心脏病在印度的检测和管理方式，” Aimil 的执行董事 Dr. Mallika Kapur 表示。“我们长期以来致力于将世界一流的医疗技术引入印度医疗生态系统，这一合作将进一步加强我们的承诺，我们相信这将使先进的分子检测在全国范围内对医生和患者可及。”</p>
<p>“我们很高兴与 Cardio Diagnostics 和 Aimil 合作，将 PrecisionCHD 引入我们的网络，” Dr. Lal PathLabs Ltd.的首席执行官 Mr. Shankha Banerjee 表示。“这次合作与我们的使命一致，即为患者、心脏病专家和医生提供最先进和可靠的诊断解决方案。通过将冠心病的分子级检测整合到我们的服务中，我们可以帮助心脏病专家和医生更早地识别疾病，并支持更有效的个性化治疗策略。”</p>
<p>此次扩展和合作强调了 Cardio Diagnostics 在全球推进精准医学的承诺，并应对世界上人口最多地区之一对心脏病早期检测和更好管理的迫切需求。</p>
<p>关于 Cardio Diagnostics</p>
<p>Cardio Diagnostics 是一家人工智能驱动的精准心血管医学公司，使心血管疾病的预防、检测和管理更加可及、个性化和精准。该公司成立的目的是进一步开发和商业化临床测试，利用专有的人工智能驱动的综合遗传 - 表观遗传引擎（“核心技术”）来改善心血管疾病的预防、检测和治疗，成为领先的医疗技术公司之一。如需更多信息，请访问 https://cdio.ai/</p>
<p>关于 Aimil</p>
<p>Aimil 成立于 1932 年，使命是将尖端技术引入印度。Aimil 在印度拥有 14 个销售和服务办公室，1000 多名员工，拥有 NABL 认证的测试和校准实验室，以及制造、研发和软件开发能力，为希望在印度专业扩展的海外公司提供增值分销。如需更多信息，请访问 https://www.aimil.com。</p>
<p>关于 Dr. Lal PathLabs</p>
<p>Dr. Lal PathLabs Limited 是印度领先的诊断和医疗相关服务提供商，以其提供准确、及时和可及的诊断解决方案而闻名。公司总部位于德里 NCR，运营着广泛的临床实验室、采样中心和取件点，每年为数百万患者提供服务。它专注于病理和放射学检测，利用尖端技术和严格的质量控制确保诊断的精准性。如需更多信息，请访问 https://www.lalpathlabs.com/。</p>
<p>前瞻性声明</p>
<p>本新闻稿中包含的某些声明和信息构成 1995 年《私人证券诉讼法》意义上的 “前瞻性声明”。在本新闻稿中使用的 “将”、“可能导致”、“预计”、“将继续”、“预期”、“估计”、“预测”、“打算”、“目标” 或类似表达，旨在识别 1995 年《私人证券诉讼改革法》意义上的 “前瞻性声明”。此类声明受到某些已知和未知的风险和不确定性的影响，其中许多超出了公司的控制范围。这些不确定性和风险包括但不限于我们成功执行增长战略的能力、法律或法规的变化、经济状况，以及依赖于《10-K 表格年度报告》中讨论的结果，该报告截至 2024 年 12 月 31 日，在第一部分的 “风险因素” 标题下，以及不时向证券交易委员会提交的其他文件。这些因素可能会对公司的财务表现产生重大不利影响，并可能导致公司未来期间的实际结果与本新闻稿中表达的任何意见或声明存在重大差异。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDc4ODIxMDhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDc4ODIxMDhyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260107882108/en/</p>
<p><strong>投资者</strong></p>
<p>投资者关系</p>
<p>855-226-9991</p>
<p>investors@cdio.ai</p>
<p><strong>媒体与公共关系</strong></p>
<p>公共关系</p>
<p>855-226-9991</p>
<p>pr@cdio.ai</p>
<p>来源：Cardio Diagnostics Holdings, Inc.</p>

CDIO

<p>Cardio Diagnostics、Aimil Ltd. 和 Dr. Lal PathLabs 合作在印度推出 PrecisionCHD™ 检测，这是 Cardio Diagnostics 在美国以外的首次扩展。该检测旨在利用人工智能和表观遗传学改善冠心病（CHD）的检测和管理。此次合作将把检测整合到 Dr. Lal PathLabs 的网络中，预计将在 2026 年进行商业推广。该合作旨在提高印度对先进心血管诊断的获取，解决日益严重的冠心病健康问题</p>

<p><em>Agreement expands Cardio Diagnostics’ global footprint and supports improved detection and management of coronary heart disease in India.</em></p>
<div class="lb-trans"><p><em>协议扩大了 Cardio Diagnostics 在全球的影响力，并支持在印度改善冠心病的检测和管理。</em></p>
</div><p>CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in epigenetics and AI-driven Precision Cardiovascular Medicine, Aimil Ltd., a company at the forefront of the instrumentation industry in India since 1932, introducing innovative, best-in-class technologies from around the world to their extensive healthcare network throughout India, and Dr. Lal PathLabs, one of India’s most trusted service provider of diagnostic and related healthcare tests with 290+ clinical laboratories and 300+ MD pathologists in their internal network, today announced a strategic agreement to launch Cardio Diagnostics’ PrecisionCHD™ test for the detection and management of coronary heart disease (CHD) in India.</p>
<div class="lb-trans"><p>芝加哥 --（商业资讯）--Cardio Diagnostics Holdings, Inc.（纳斯达克：CDIO），一家在表观遗传学和人工智能驱动的精准心血管医学领域的领导者，Aimil Ltd.，自 1932 年以来在印度仪器行业处于前沿，向其广泛的医疗网络引入来自全球的创新一流技术，以及 Dr. Lal PathLabs，印度最受信赖的诊断及相关医疗测试服务提供商之一，拥有 290 多个临床实验室和 300 多名内部网络的医学博士，今天宣布达成战略协议，在印度推出 Cardio Diagnostics 的 PrecisionCHD™测试，以检测和管理冠心病（CHD）。</p>
</div><p>This partnership marks Cardio Diagnostics’ first expansion outside the United States and official entry into the Indian market. It also represents a major step toward making Cardio Diagnostics’ advanced technology accessible in India, where cardiovascular disease remains a leading and growing health concern. The prevalence of CHD in India varies by population settings, with a prevalence of up to 7.4% and 13% reported in rural and urban areas, respectively.</p>
<div class="lb-trans"><p>此次合作标志着 Cardio Diagnostics 首次在美国以外扩展，并正式进入印度市场。这也是朝着使 Cardio Diagnostics 的先进技术在印度可及迈出的重要一步，在印度，心血管疾病仍然是一个主要且日益严重的健康问题。冠心病在印度的流行率因人群设置而异，农村和城市地区的流行率分别高达 7.4% 和 13%。</p>
</div><p>PrecisionCHD is a clinical blood test that can detect CHD at a molecular level by combining the science of epigenetics and genetics with AI technology. This clinically validated test delivers actionable insights that can help physicians understand the key molecular drivers of disease, crucial for personalized treatment, as well as ongoing management. In addition to detecting obstructive CHD, which angiograms can also detect, the PrecisionCHD test can detect non-obstructive CHD, which angiograms typically cannot detect. Data supporting PrecisionCHD’s ability to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA), which are two common forms of non-obstructive disease, were recently presented at the American Heart Association Scientific Sessions held in New Orleans, LA.</p>
<div class="lb-trans"><p>PrecisionCHD 是一种临床血液检测，可以通过结合表观遗传学和遗传学的科学与人工智能技术，在分子水平上检测冠心病。这种经过临床验证的测试提供可操作的见解，帮助医生理解疾病的关键分子驱动因素，这对个性化治疗和持续管理至关重要。除了检测阻塞性冠心病（也可以通过血管造影检测到），PrecisionCHD 测试还可以检测非阻塞性冠心病，而血管造影通常无法检测到。支持 PrecisionCHD 检测无阻塞冠状动脉缺血（INOCA）和无阻塞冠状动脉心肌梗死（MINOCA）的数据，最近在美国心脏协会在路易斯安那州新奥尔良举行的科学会议上进行了展示。</p>
</div><p>The initial phase of this partnership has begun and is focused on integrating and promoting the test within Dr. Lal PathLabs’ extensive laboratory and clinical network, ensuring alignment with Indian clinical and regulatory protocols. Once established, efforts will be focused on ramping up commercial rollout, which is expected in 2026.</p>
<div class="lb-trans"><p>此次合作的初始阶段已经开始，重点是将测试整合并推广到 Dr. Lal PathLabs 广泛的实验室和临床网络中，确保与印度的临床和监管协议保持一致。一旦建立，将重点放在加速商业推广上，预计将在 2026 年进行。</p>
</div><p>“We are thrilled to partner with Aimil and Dr. Lal PathLabs to bring PrecisionCHD to India,” said Dr. Meesha Dogan, CEO and co-founder of Cardio Diagnostics. “This partnership is a major step forward in democratizing access to advanced cardiovascular diagnostics and is a result of our ongoing effort to expand the reach of our technology beyond the U.S. market.”</p>
<div class="lb-trans"><p>“我们很高兴与 Aimil 和 Dr. Lal PathLabs 合作，将 PrecisionCHD 引入印度，” Cardio Diagnostics 的首席执行官兼联合创始人 Dr. Meesha Dogan 表示。“这次合作是使先进心血管诊断普及的重要一步，也是我们不断努力将技术推广到美国市场以外的结果。”</p>
</div><p>“Partnering with Cardio Diagnostics and Dr. Lal PathLabs enables us to deliver cutting-edge cardiovascular diagnostics that can transform how heart disease is detected and managed in India,” said Dr. Mallika Kapur, Executive Director of Aimil. “Our longstanding commitment to bringing world-class medical technologies to the Indian healthcare ecosystem is strengthened by this collaboration, which we believe will make advanced molecular testing accessible to physicians and patients nationwide.”</p>
<div class="lb-trans"><p>“与 Cardio Diagnostics 和 Dr. Lal PathLabs 的合作使我们能够提供尖端的心血管诊断，改变心脏病在印度的检测和管理方式，” Aimil 的执行董事 Dr. Mallika Kapur 表示。“我们长期以来致力于将世界一流的医疗技术引入印度医疗生态系统，这一合作将进一步加强我们的承诺，我们相信这将使先进的分子检测在全国范围内对医生和患者可及。”</p>
</div><p>“We are pleased to collaborate with Cardio Diagnostics and Aimil to bring PrecisionCHD to our network,” said Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs Ltd. “This partnership aligns with our mission to be the leader in providing patients, cardiologists and physicians with the most advanced and reliable diagnostic solutions. By integrating molecular-level detection of coronary heart disease into our services, we can help cardiologists and physicians identify disease earlier and support more effective, personalized treatment strategies.”</p>
<div class="lb-trans"><p>“我们很高兴与 Cardio Diagnostics 和 Aimil 合作，将 PrecisionCHD 引入我们的网络，” Dr. Lal PathLabs Ltd.的首席执行官 Mr. Shankha Banerjee 表示。“这次合作与我们的使命一致，即为患者、心脏病专家和医生提供最先进和可靠的诊断解决方案。通过将冠心病的分子级检测整合到我们的服务中，我们可以帮助心脏病专家和医生更早地识别疾病，并支持更有效的个性化治疗策略。”</p>
</div><p>This expansion and collaboration underscore Cardio Diagnostics’ commitment to advancing precision medicine globally and addressing the urgent need for early detection and better management of heart disease in one of the world’s most populous regions.</p>
<div class="lb-trans"><p>此次扩展和合作强调了 Cardio Diagnostics 在全球推进精准医学的承诺，并应对世界上人口最多地区之一对心脏病早期检测和更好管理的迫切需求。</p>
</div><p>About Cardio Diagnostics</p>
<div class="lb-trans"><p>关于 Cardio Diagnostics</p>
</div><p>Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/</p>
<div class="lb-trans"><p>Cardio Diagnostics 是一家人工智能驱动的精准心血管医学公司，使心血管疾病的预防、检测和管理更加可及、个性化和精准。该公司成立的目的是进一步开发和商业化临床测试，利用专有的人工智能驱动的综合遗传 - 表观遗传引擎（“核心技术”）来改善心血管疾病的预防、检测和治疗，成为领先的医疗技术公司之一。如需更多信息，请访问 https://cdio.ai/</p>
</div><p>About Aimil</p>
<div class="lb-trans"><p>关于 Aimil</p>
</div><p>Aimil was founded in 1932, with a mission to bring leading edge technologies to India. With 14 sales and service offices across India, 1000+ employees, NABL certified testing and calibration laboratories, and manufacturing, R&amp;D &amp; software development capability, Aimil offers value-added distribution to overseas companies wanting to expand professionally in India. For more information, please visit https://www.aimil.com.</p>
<div class="lb-trans"><p>Aimil 成立于 1932 年，使命是将尖端技术引入印度。Aimil 在印度拥有 14 个销售和服务办公室，1000 多名员工，拥有 NABL 认证的测试和校准实验室，以及制造、研发和软件开发能力，为希望在印度专业扩展的海外公司提供增值分销。如需更多信息，请访问 https://www.aimil.com。</p>
</div><p>About Dr. Lal PathLabs</p>
<div class="lb-trans"><p>关于 Dr. Lal PathLabs</p>
</div><p>Dr. Lal PathLabs Limited is a premier provider of diagnostic and healthcare-related services in India, renowned for its commitment to delivering accurate, timely, and accessible diagnostic solutions. Headquartered in Delhi NCR, the company operates an extensive network of clinical laboratories, collection centers, and pick-up points, catering to millions of patients annually. It specializes in pathology and radiology testing, leveraging cutting-edge technology and stringent quality controls to ensure precision in diagnostics. For more information, visit https://www.lalpathlabs.com/.</p>
<div class="lb-trans"><p>Dr. Lal PathLabs Limited 是印度领先的诊断和医疗相关服务提供商，以其提供准确、及时和可及的诊断解决方案而闻名。公司总部位于德里 NCR，运营着广泛的临床实验室、采样中心和取件点，每年为数百万患者提供服务。它专注于病理和放射学检测，利用尖端技术和严格的质量控制确保诊断的精准性。如需更多信息，请访问 https://www.lalpathlabs.com/。</p>
</div><p>Forward-Looking Statements</p>
<div class="lb-trans"><p>前瞻性声明</p>
</div><p>Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.</p>
<div class="lb-trans"><p>本新闻稿中包含的某些声明和信息构成 1995 年《私人证券诉讼法》意义上的 “前瞻性声明”。在本新闻稿中使用的 “将”、“可能导致”、“预计”、“将继续”、“预期”、“估计”、“预测”、“打算”、“目标” 或类似表达，旨在识别 1995 年《私人证券诉讼改革法》意义上的 “前瞻性声明”。此类声明受到某些已知和未知的风险和不确定性的影响，其中许多超出了公司的控制范围。这些不确定性和风险包括但不限于我们成功执行增长战略的能力、法律或法规的变化、经济状况，以及依赖于《10-K 表格年度报告》中讨论的结果，该报告截至 2024 年 12 月 31 日，在第一部分的 “风险因素” 标题下，以及不时向证券交易委员会提交的其他文件。这些因素可能会对公司的财务表现产生重大不利影响，并可能导致公司未来期间的实际结果与本新闻稿中表达的任何意见或声明存在重大差异。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDc4ODIxMDhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260107882108r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260107882108/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260107882108/en/</p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>855-226-9991</p>
<div class="lb-trans"><p>855-226-9991</p>
</div><p>investors@cdio.ai</p>
<div class="lb-trans"><p>investors@cdio.ai</p>
</div><p><strong>Media &amp; Public Relations</strong></p>
<div class="lb-trans"><p><strong>媒体与公共关系</strong></p>
</div><p>Public Relations</p>
<div class="lb-trans"><p>公共关系</p>
</div><p>855-226-9991</p>
<div class="lb-trans"><p>855-226-9991</p>
</div><p>pr@cdio.ai</p>
<div class="lb-trans"><p>pr@cdio.ai</p>
</div><p>Source: Cardio Diagnostics Holdings, Inc.</p>
<div class="lb-trans"><p>来源：Cardio Diagnostics Holdings, Inc.</p>
</div>

Cardio Diagnostics、Aimil Ltd. 和 Dr. Lal PathLabs Limited 合作在印度推出 PrecisionCHD™ 测试 | CDIO 股票新闻